Company Profile
Seres Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Seres Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Seres Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Seres Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Seres Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
MCRB is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Seres is still working its live biotherapeutic franchise, with SER-155 the clearest item to watch. The investigator-sponsored study in immune checkpoint-related enterocolitis gives the company a practical next readout while it keeps the broader inflammatory pipeline in view.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Source: Seres Therapeutics
- 02
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Source: Seres Therapeutics
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.